Gómez-Casares, M T <br/><br/>
MYC antagonizes the differentiation induced by imatinib in chronic myeloid leukemia cells through downregulation of p27(KIP1.).  [electronic resource] 

 -  Oncogene  Apr 2013 
 - 2239-46 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1476-5594 
<br/><br/><label>Standard No.: </label>10.1038/onc.2012.246  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Antineoplastic Agents--pharmacology<br/>Benzamides--pharmacology<br/>Cell Differentiation<br/>Cell Line, Tumor<br/>Cell Proliferation<br/>Cyclin-Dependent Kinase Inhibitor p27--genetics<br/>Dasatinib<br/>Down-Regulation<br/>Erythroid Cells--drug effects<br/>Gene Expression<br/>Gene Expression Regulation, Leukemic<br/>Humans<br/>Imatinib Mesylate<br/>Leukemia, Myelogenous, Chronic, BCR-ABL Positive<br/>Piperazines--pharmacology<br/>Proto-Oncogene Proteins c-myc--physiology<br/>Pyrimidines--pharmacology<br/>S-Phase Kinase-Associated Proteins--metabolism<br/>Thiazoles--pharmacology<br/>beta-Globins--genetics